Shining a Light on Commitment to Hematology

Shining a Light on Commitment to Hematology

By Janice Staber, MD Sriram Krishnaswamy, PhD, and Jeffrey Weitz, MD, FRCPC, are the recipients of the 2019 Ernest Beutler Lecture and Prize. Dr. Ernest Beutler’s first research publication in 1952 initiated his long-standing career in science and eventually...

Final Flourish: Sensational Late-Breaking Abstracts

By Binod Dhakal, MD, MS Each year on the final day of the ASH annual meeting, the Late-Breaking Abstracts (LBAs) Session presents novel, substantive, and groundbreaking research that was not available in time for the standard ASH abstract submission deadline. And if...

A New Era for Sickle Cell Disease, Acute Porphyria, and More

By Basem M. William, MD On Monday, the Director of the Division of Hematology Products in the Office of Hematology and Oncology Products at the U.S. Food and Drug Administration (FDA), Ann Farrell, MD, chaired the two special ASH-FDA Joint Symposia focusing on new...

From Left Behind to Front and Center

By Janice Staber, MD There have been years when the hemostasis and thrombosis community might have felt a little left behind at the ASH annual meeting. However, here in Orlando, sessions on hemostasis and thrombosis were discussed front and center. From the...

Presidential Symposium: Big Ideas for Big Data

By Ahmar U. Zaidi, MD “In God we trust. All others must bring data.” The amount of data generated from the dawn of humanity until 2003 was 5 exabytes. Since then, 5 exabytes of data are created every two days. There is no doubt that our ability to collect and store...
Two-Hits to Catastrophic

Two-Hits to Catastrophic

By Janice Staber, MD In 1971, Alfred Knudson, MD, PhD, originally formulated the two-hit hypothesis, which states that most genes require two mutations for a change to occur; this aided the medical community’s understanding of how tumors form. We now know that the...
A Disruptive Innovation?

A Disruptive Innovation?

By Binod Dhakal, MD, MS “I just want to be a normal person, doctor,” Greg said, “but that’s not an option.” Greg, 58 years old, underwent hematopoietic stem cell transplantation (HSCT) for high-risk acute myeloid leukemia (AML) three years ago using cells from his...

Best Donor Choice: It’s in the Eye of the Beholder!

By Basem M. William, MD One of the major leaps in hematopoietic stem cell transplantation (HSCT) is the increasingly successful use of alternative donors, thereby allowing the delivery of a potentially curative transplant to approximately 75 percent of patients who do...
Erythroferrone: A Bone to Pick with Thalassemia

Erythroferrone: A Bone to Pick with Thalassemia

By Alexander Glaros, MD, and Ahmar U. Zaidi, MD If the results of the past five years are any indication, the era of gene therapy is truly at hand, and nearly 100 years after Thomas Cooley first described the skeletal and morphological changes of the disease in a pair...
Aging: Attack of the Clones

Aging: Attack of the Clones

By Binod Dhakal, MD, MS “Aging is not lost youth but a new stage of opportunity and strength.” — Betty Friedan (1921-2006) Blood cells originate from hematopoietic stem cells (HSCs). Adult HSCs are maintained in a quiescent state, a state necessary for preserving the...

Dazed and Con-Bruised?

By Alexander Glaros, MD, and Ahmar U. Zaidi, MD In 1971, then-President Richard Nixon declared drug abuse to be “public enemy number one,” and The War on Drugs was born. It has now been nearly 50 years since the dawn of what proved to be a seismic shift in the focus...

SCD Roundup

By Ahmar U. Zaidi, MD “No conclusions can be drawn from this case. Not even a definite diagnosis can be made,” James Herrick wrote in 1910 about the case of the first known patient in America with sickle cell disease (SCD), Walter Clement Noel. More than one century...

The Road to Wisdom: ASH-ASPHO Pediatric Choosing Wisely Collaboration

By Lynn Malec, MD, MSc, and Janice Staber, MD “We are made wise not by the recollection of our past, but by the responsibility for our future.”  – George Bernard Shaw The Choosing Wisely® campaign is an effort led by the American Board of Internal Medicine...
Cutting Costs for CML Abroad

Cutting Costs for CML Abroad

By Ilana Yurkiewicz, MD “If you have to get cancer,” I once reassured a frightened patient, “CML [chronic myeloid leukemia] isn’t bad.” CML is truly one of our cancer success stories. The identification of a single genetic swap — BCR-ABL — and the development of...
The Roman God of Portals and More

The Roman God of Portals and More

By Binod Dhakal, MD, MS In 1951 a renowned hematologist from Harvard University, William Dameshek, MD, wrote an editorial in Blood providing seminal insight into myeloproliferative neoplasms (MPNs) — a group of disorders characterized by expansion of different myeloid...

One-Size-Fits-All for AML? Not Anymore

By Ilana Yurkiewicz, MD Once upon a time, there was “7+3.” Developed in the 1970s, this easy-to-remember induction chemotherapy regimen for acute myeloid leukemia (AML) went largely unchanged for decades. But in the past few years, we have seen multiple new drug...

I AM IRONMAN!

By Alexander K. Glaros, MD, and Ahmar U. Zaidi, MD If you’re a nerd like… Scratch that…If you’re in Orlando this week, it’s either because you have a favorite blood cell type (gotta be the sea blue histiocyte) or you still haven’t given up on your...

Blood Counts: Reducing the Burden of Red Blood Cell Transfusions

By Ahmar U. Zaidi, MD The first transfusions in the 19th century were rife with adverse events, poor outcomes, and even patient deaths. To no one’s surprise then, medical providers became dubious of this “dangerous” procedure. It was after Landsteiner and Jansky...

Constructing an Idea: From Wings to Landing Gear

By Janice Staber, MD “Great ideas need landing gear as well as wings.” — Charles Douglas Jackson In the Special-Interest Session, Systems-Based Hematology: How to Implement Evidence-Based Programs for Virtual Hematology Consults and Anticoagulation Stewardship, Michal...

Sunday’s Continuing Conversations With the Speakers

Continuing Conversations with the Speakers sessions allow for informal discussions with Scientific Program session speakers that will give interested individuals, especially trainees and junior investigators, increased accessibility both to information on the topic...